These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly. Stolk MF; van Erpecum KJ; Koppeschaar HP; de Bruin WI; Jansen JB; Lamers CB; van Berge Henegouwen GP Gut; 1993 Jun; 34(6):808-13. PubMed ID: 8314514 [TBL] [Abstract][Full Text] [Related]
31. In vivo inhibitory effect of lanreotide (BIM 23014), a new somatostatin analog, on prostaglandin- and cholera toxin-stimulated intestinal fluid in the rat. Botella A; Vabre F; Fioramonti J; Thomas F; Bueno L Peptides; 1993; 14(2):297-301. PubMed ID: 8097869 [TBL] [Abstract][Full Text] [Related]
32. Inhibitory actions of a somatostatin analog SMS 201-995 on endocrine secretion from the isolated perfused stomach and pancreas of the rat. Verchere CB; Kwok YN; Brown JC Pharmacology; 1993; 46(1):50-60. PubMed ID: 8094569 [TBL] [Abstract][Full Text] [Related]
33. The effect of an octapeptide somatostatin analogue (SMS 201-995) and somatostatin-14 (SST-14) on pentagastrin-stimulated gastric acid secretion: a comparative study in man. Whitehouse I; Beglinger C; Fried M; Gyr K Hepatogastroenterology; 1984 Oct; 31(5):227-9. PubMed ID: 6150888 [TBL] [Abstract][Full Text] [Related]
34. Effect of a new oral somatostatin analog (SDZ CO 611) on gastric emptying, mouth to cecum transit time, and pancreatic and gut hormone release in normal male subjects. Nelson-Piercy C; Hammond PJ; Gwilliam ME; Khandan-Nia N; Myers MJ; Ghatei MA; Bloom SR J Clin Endocrinol Metab; 1994 Feb; 78(2):329-36. PubMed ID: 7906279 [TBL] [Abstract][Full Text] [Related]
35. The significance of somatostatin analogues in the antiproliferative treatment of carcinomas. Kath R; Höffken K Recent Results Cancer Res; 2000; 153():23-43. PubMed ID: 10626287 [TBL] [Abstract][Full Text] [Related]
36. Effect of octreotide on pancreatic endocrine function in partial pancreatectomy. Presti M; Niehoff M; Rioux J; Burton F; Garvin P J Surg Res; 1996 Mar; 61(2):449-53. PubMed ID: 8656623 [TBL] [Abstract][Full Text] [Related]
37. Somatostatin for upper gastrointestinal hemorrhage and pancreatic surgery. A review of its pharmacology and safety. Scarpignato C; Pelosini I Digestion; 1999; 60 Suppl 3():1-16. PubMed ID: 10567784 [TBL] [Abstract][Full Text] [Related]
38. Galanin potentiates supramaximal caerulein-stimulated pancreatic amylase secretion via its action on somatostatin secretion. Barreto SG; Carati CJ; Schloithe AC; Toouli J; Saccone GT Am J Physiol Gastrointest Liver Physiol; 2009 Dec; 297(6):G1268-73. PubMed ID: 19779018 [TBL] [Abstract][Full Text] [Related]
39. Review article: the relative effectiveness of somatostatin and octreotide therapy in pancreatic disease. Jenkins SA; Berein A Aliment Pharmacol Ther; 1995 Aug; 9(4):349-61. PubMed ID: 8527611 [TBL] [Abstract][Full Text] [Related]
40. Effect of somatostatin analogue octreotide injected into the third cerebral ventricle on pentagastrin-induced gastric acid secretion in rats. Gao F; Hu XF World J Gastroenterol; 2006 May; 12(17):2767-9. PubMed ID: 16718766 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]